Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) - in Atrial Fibrillation
Latest Information Update: 14 Oct 2024
At a glance
- Drugs Edoxaban (Primary) ; Fluindione; Phenindione; Phenprocoumon; Vitamin K antagonists; Warfarin
- Indications Embolism and thrombosis; Myocardial infarction; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms ENVISAGE-TAVI AF
- Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
- 13 Nov 2023 Results of post hoc sub-analysis assessing whether efficacy and safety of EDO vs VKA in patients with AF undergoing TAVR will vary across the range of baseline CrCl, presented at the American Heart Association Scientific Sessions 2023
- 13 Nov 2023 Results analyzing association between anticoagulation treatment duration and patient-reported outcomes (PROs) and treatment satisfaction, presented at the American Heart Association Scientific Sessions 2023
- 14 Oct 2023 Results of a Post Hoc Analysis comparing effects of Edoxaban and Vitamin K Antagonists in patients with Atrial Fibrillation after Transcatheter Aortic Valve Replacement, presented at the American Journal of Cardiology.